Nanoparticle-mediated siRNA delivery is a complex process that requires transport across numerous extracellular and intracellular barriers. As such, the development of nanoparticles for efficient delivery would benefit from an understanding of how parameters associated with these barriers relate to the physicochemical properties of nanoparticles. Here, we use a multiparametric approach for the evaluation of lipid nanoparticles (LNPs) to identify relationships between structure, biological function, and biological activity. Our results indicate that evaluation of multiple parameters associated with barriers to delivery such as siRNA entrapment, pK[subscript a], LNP stability, and cell uptake as a collective may serve as a useful prescreening...
A significant challenge in the development of clinically viable siRNA delivery systems is a lack of ...
Nanoparticle drug delivery vehicles can be used for in vivo delivery of a variety of bioactive molec...
Lipid nanoparticles (LNP) are currently the most advanced delivery systems for enabling siRNA to be ...
Because nanoparticles with diameters less than 50 nm penetrate stromal-rich tumor tissues more effic...
A significant challenge in the development of clinically-viable siRNA delivery systems is a lack of ...
Lipid nanoparticles (LNPs) are currently having an increasing impact on nanomedicines as delivery ag...
Lipid nanoparticles (LNPs) are currently having an increasing impact on nanomedicines as delivery ag...
Thesis: Ph. D., Massachusetts Institute of Technology, Department of Biology, 2016.Cataloged from PD...
Macromolecules such as nucleic acids and inorganic nanoparticles require a delivery vector to capit...
Effective delivery of small interfering RNA (siRNA) requires efficient cellular uptake and release i...
Thesis: Ph. D., Massachusetts Institute of Technology, Department of Chemical Engineering, 2017.Cata...
Lipid nanoparticles (LNPs) are currently the most clinically advanced nonviral carriers for the deli...
Synthetic short interfering RNA (siRNA) oligonucleotides can trigger the RNA interference pathway an...
Nucleic acid therapeutics involves the use of polynucleotides (DNA, RNA) as novel therapeutic agents...
Lipid nanoparticles (LNPs) are currently the most clinically advanced nonviral carriers for the deli...
A significant challenge in the development of clinically viable siRNA delivery systems is a lack of ...
Nanoparticle drug delivery vehicles can be used for in vivo delivery of a variety of bioactive molec...
Lipid nanoparticles (LNP) are currently the most advanced delivery systems for enabling siRNA to be ...
Because nanoparticles with diameters less than 50 nm penetrate stromal-rich tumor tissues more effic...
A significant challenge in the development of clinically-viable siRNA delivery systems is a lack of ...
Lipid nanoparticles (LNPs) are currently having an increasing impact on nanomedicines as delivery ag...
Lipid nanoparticles (LNPs) are currently having an increasing impact on nanomedicines as delivery ag...
Thesis: Ph. D., Massachusetts Institute of Technology, Department of Biology, 2016.Cataloged from PD...
Macromolecules such as nucleic acids and inorganic nanoparticles require a delivery vector to capit...
Effective delivery of small interfering RNA (siRNA) requires efficient cellular uptake and release i...
Thesis: Ph. D., Massachusetts Institute of Technology, Department of Chemical Engineering, 2017.Cata...
Lipid nanoparticles (LNPs) are currently the most clinically advanced nonviral carriers for the deli...
Synthetic short interfering RNA (siRNA) oligonucleotides can trigger the RNA interference pathway an...
Nucleic acid therapeutics involves the use of polynucleotides (DNA, RNA) as novel therapeutic agents...
Lipid nanoparticles (LNPs) are currently the most clinically advanced nonviral carriers for the deli...
A significant challenge in the development of clinically viable siRNA delivery systems is a lack of ...
Nanoparticle drug delivery vehicles can be used for in vivo delivery of a variety of bioactive molec...
Lipid nanoparticles (LNP) are currently the most advanced delivery systems for enabling siRNA to be ...